Table 3 Clinical trials of CAR T-cell therapy in recurrent GB.
From: Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects
Trials | No. | Delivery routes | Target | Molecular characteristic | Toxicity | Phase | Results |
|---|---|---|---|---|---|---|---|
NCT00730613 | 3 | IC | IL13Rα2 | NA | No grade 3 or higher | I | 1 pt with reduced IL13Rα2 expression; 1 pt with an increment of TNV |
NCT01109095 | 17 | IV | Her2 | NA | No dose-limiting toxic effects | I | 1 pt with PR > 9 m; 7pts with SD for 8w to 29 m; 3pts with SD for 24-29 m; mOS: 24.5 m |
NCT02442297 | 28 | IC | Her2 | NA | NA | I | NA |
NCT02208362 | 1 | IC then IV | IL13Rα2 | MGMT non met IDH1 WT | No grade 3 or higher | I | Regression of all tumors; increment of cytokines and immune cells; clinical response for 7.5 m |
NCT02209376 | 10 | IV | EGFRvIII | MGMT non met | No off-tumor toxicity or cytokine release syndrome | I | 1 pt with SD > 18 m; mOS:251days increment of inhibitory molecules and Treg |
NCT02844062 | 20 | IC | EGFRvIII | NA | NA | I | NA |
NCT02937844 | 20 | IV | Anti-PD-L1 CSR T cells | NA | NA | I | NA |
NCT03170141 | 20 | IV or IC | EGFRvIII | NA | NA | I | NA |
NCT03389230 | 42 | IT | HER2-CD3ζ-CD19t | NA | NA | I | NA |
NCT03283631 | 24 | IC | EGFRvIII | NA | NA | I | NA |
NCT04045847 | 31 | IC | CD147 | NA | NA | I | NA |
NCT04385173 | 12 | IT | CD276 | NA | NA | I | NA |
NCT04077866 | 40 | IT | CD276 | NA | NA | I/II | NA |
NCT04214392 | 36 | IV | CD28-CD3ζ-CD19t | MMP2+ | NA | I | NA |
NCT04077866 | 100 | IC | B7-H3 | NA | No off-tumor toxicity | II | Effectively control tumor growth |
